Market Overview

Morgan Stanley Sees Johnson & Johnson Taking Rx Estimates Higher

Related JNJ
Can You Guess This Chart?
Goldman Says These 25 Healthcare Stocks Are Immune To The Election
GlaxoSmithKline: Has Q3 2016 Seen The Positive Momentum Continue Building? (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Johnson & Johnson (NYSE: JNJ).

In the report, Morgan Stanley noted, “We're adjusting our pharma estimates modestly to reflect our changing market views and July sales and prescriptions data from IMS. Overall. we're taking our 2016 pharma sales estimates up by 3%, driving a 2% revision in EPS. The largest swing factors include Imbruvica and Invokana.”

Johnson & Johnson closed on Friday at $103.73.

Latest Ratings for JNJ

Sep 2016JefferiesMaintainsHold
Aug 2016JefferiesMaintainsHold
Jul 2016Argus ResearchUpgradesHoldBuy

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (JNJ)

View Comments and Join the Discussion!